AV-101 is an investigational, proprietary dry powder inhaled formulation of imatinib which is intended to address the underlying hyperproliferation of cells within the narrowed arteries of the lungs. It is designed to deliver antiproliferative therapy directly to the lungs, allowing more of the drug to access the diseased tissues directly while simultaneously reducing systemic exposure (which was an issue with the previous oral formulation).
Learn more about this study at this link on the aerovate therapeutics website
See also at this link for the entry on the clinicaltrials.gov website
Disclaimer
While every possible effort will be taken to ensure that the Pulmonary Hypertension Knowledge Sharing Platform content is accurate and up-to-date, it may still include opinions of experts that are the best knowledge at the time of publication but may now be outdated, and materials that are otherwise inaccurate or incomplete. We invite visitors to consult with their health care professionals before making any decisions based upon them.